MAIA Biotechnology Inc. Financials

MAIA Biotechnology Inc. (MAIA) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, MAIA Biotechnology Inc. (MAIA) reported a net income of -$23.3M in fiscal year 2024.

MAIA Biotechnology Inc. (MAIA) reported diluted earnings per share of $-1.05 for fiscal year 2024. This represents a 29.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MAIA Biotechnology Inc. (MAIA) generated -$15.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

MAIA Biotechnology Inc. (MAIA) had $10.2M in total assets as of fiscal year 2024, including both current and long-term assets.

MAIA Biotechnology Inc. (MAIA) invested $10.0M in research and development during fiscal year 2024.

MAIA Biotechnology Inc. (MAIA) had 26M shares outstanding as of fiscal year 2024.

MAIA Biotechnology Inc. (MAIA) had a current ratio of 2.65 as of fiscal year 2024, which is generally considered healthy.

MAIA Biotechnology Inc. (MAIA) had a debt-to-equity ratio of 1.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

MAIA Biotechnology Inc. (MAIA) had a return on assets of -229.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, MAIA Biotechnology Inc. (MAIA) had $0 in cash against an annual operating cash burn of $15.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

MAIA Biotechnology Inc. (MAIA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

MAIA Biotechnology Inc. (MAIA) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

MAIA Biotechnology Inc. (MAIA) has an interest coverage ratio of -297494.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.